Bilateral BBSRC-SFI Innate immune signalling underpinning Klebsiella-host interactions

双边 BBSRC-SFI 先天免疫信号传导支撑克雷伯氏菌与宿主相互作用

基本信息

  • 批准号:
    BB/P020194/1
  • 负责人:
  • 金额:
    $ 59.67万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Research Grant
  • 财政年份:
    2017
  • 资助国家:
    英国
  • 起止时间:
    2017 至 无数据
  • 项目状态:
    已结题

项目摘要

Our struggle against infectious diseases is far from over. Globalisation has increased the risk of pandemics, and the rise of antibiotic-resistant microbes threatens to render existing drugs useless. Of particular concern is the health burden of respiratory infections being the UK in the top 25 countries for deaths from acute respiratory infections, above most other European countries. It is therefore urgent and necessary to develop new therapeutics based on new concepts and approaches. This is particularly important in the case of Klebsiella infections showing a 12% increased incidence over the last five years within the UK alone. In fact, the increasing isolation of strains resistant to "last resort" antimicrobials has significantly narrowed, or in some settings completely removed, the therapeutic options for the treatment of Klebsiella infections. Unfortunately, at present, we cannot identify candidate compounds in late-stage development for treatment of multidrug Klebsiella infections; this pathogen is exemplary of the mismatch between unmet medical needs and the current antimicrobial research and development pipeline. Alarmingly, recent studies have recognized that several Klebsiella virulent and multidrug resistant isolates have access to a mobile pool of virulence and antimicrobial resistance genes; hence making possible the emergence of a multidrug resistant, hypervirulent K. pneumoniae isolate capable of causing untreatable infections in healthy individuals. However, our understanding of Klebsiella pathogenesis still contains considerable gaps thereby making a compelling case to better understand Klebsiella infection biology in the context of the complex interactions between bacterial pathogens and their hosts.In this proposal, by combining the distinct but synergistic expertise and experience across the disciplines of molecular and cellular microbiology, biochemistry, and immunology, of the Bengoechea (UK) and Bowie (Ireland) laboratories we will better understand the various Achilles heels of host defense, and thereby more precisely shore-up these vulnerable hot spots while deconstructing the strategies used by Klebsiella to survive within the infected tissue. Our efforts will expose a Klebsiella anti-immune strategy based on co-opting functions (receptors and immune signals) implicated in antimicrobial defense. This remarkable strategy is radically different to those employ by other well studied bacterial pathogens which disrupt host defenses instead of hijacking them like Klebsiella. Harnessing the host-pathogen interface opens the avenue for new antimicrobial therapeutics. Interference with pathogen virulence and/or signalling pathways hijacked by pathogens for their own benefit is an especially compelling approach, as it is thought to apply less selective pressure for the development of resistance than traditional strategies, which are aimed at killing pathogens or preventing their growth. There is extensive research on the pathways targeted by Klebsiella, and new drugs are currently under development. We anticipate that the outcomes of this proposal would lead to test these drugs in pre-clinical models of klebsiella disease hence allowing a potential fast-track transition from the basic research to clinical development.
我们与传染病的斗争远未结束。全球化增加了大流行的风险,抗药性微生物的崛起有可能使现有药物失效。尤其令人担忧的是,在急性呼吸道感染死亡人数最多的25个国家中,英国的呼吸道感染造成的健康负担高于其他大多数欧洲国家。因此,基于新的概念和方法开发新的治疗方法是迫切和必要的。这在克雷伯氏菌感染的情况下尤其重要,仅在英国,在过去五年中,克雷伯菌感染的发病率增加了12%。事实上,越来越多的耐“最后手段”抗菌素菌株的分离已经大大缩小了治疗克雷伯氏菌感染的选择范围,甚至在某些情况下完全取消了这一选择。不幸的是,目前,我们还不能在治疗多药克雷伯氏菌感染的后期开发中确定候选化合物;这种病原体是未得到满足的医疗需求与当前抗菌素研发管道之间不匹配的典范。令人担忧的是,最近的研究已经认识到,几个克雷伯氏菌毒力和多药耐药分离株可以访问毒力和抗菌素耐药基因库;因此,可能出现多药耐药、超强毒力的肺炎克雷伯菌分离株,能够在健康个体中造成无法治疗的感染。然而,我们对克雷伯氏菌发病机制的理解仍然存在相当大的差距,从而为在细菌病原体与宿主之间复杂相互作用的背景下更好地理解克雷伯氏菌感染生物学提供了一个引人注目的案例。在这项建议中,通过结合本戈切亚(英国)和鲍伊(爱尔兰)实验室在分子和细胞微生物学、生物化学和免疫学领域独特但协同的专业知识和经验,我们将更好地了解宿主防御的各种跟腱,从而更准确地支撑这些脆弱的热点,同时解构克雷伯氏菌在感染组织中生存所使用的策略。我们的努力将揭示一种基于参与抗菌防御的增选功能(受体和免疫信号)的克雷伯氏菌抗免疫策略。这一显着的策略与其他经过充分研究的细菌病原体使用的策略截然不同,后者扰乱了宿主的防御,而不是像克雷伯氏菌那样劫持它们。利用宿主-病原体界面为新的抗菌疗法开辟了道路。干扰病原体的毒力和/或被病原体为了自身利益劫持的信号通路是一种特别引人注目的方法,因为与旨在杀死病原体或防止其生长的传统策略相比,这被认为对发展抗药性施加的选择性压力较小。人们对克雷伯氏菌的靶向途径进行了广泛的研究,目前正在开发新药。我们预计,这项提议的结果将导致在克雷伯氏菌病的临床前模型中测试这些药物,从而允许从基础研究到临床开发的潜在快速过渡。

项目成果

期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Natural killer cell-intrinsic type I IFN signaling controls Klebsiella pneumoniae growth during lung infection.
  • DOI:
    10.1371/journal.ppat.1006696
  • 发表时间:
    2017-11
  • 期刊:
  • 影响因子:
    6.7
  • 作者:
    Ivin M;Dumigan A;de Vasconcelos FN;Ebner F;Borroni M;Kavirayani A;Przybyszewska KN;Ingram RJ;Lienenklaus S;Kalinke U;Stoiber D;Bengoechea JA;Kovarik P
  • 通讯作者:
    Kovarik P
Myeloid cell nuclear differentiation antigen controls the pathogen-stimulated type I interferon cascade in human monocytes by transcriptional regulation of IRF7.
  • DOI:
    10.1038/s41467-021-27701-x
  • 发表时间:
    2022-01-10
  • 期刊:
  • 影响因子:
    16.6
  • 作者:
    Gu L;Casserly D;Brady G;Carpenter S;Bracken AP;Fitzgerald KA;Unterholzner L;Bowie AG
  • 通讯作者:
    Bowie AG
In vivo single-cell transcriptomics reveal Klebsiella pneumoniae skews lung macrophages to promote infection.
  • DOI:
    10.15252/emmm.202216888
  • 发表时间:
    2022-12-07
  • 期刊:
  • 影响因子:
    11.1
  • 作者:
    Dumigan, Amy;Cappa, Oisin;Morris, Brenda;Pessoa, Joana Sa;Calderon-Gonzalez, Ricardo;Mills, Grant;Lancaster, Rebecca;Simpson, David;Kissenpfennig, Adrien;Bengoechea, Jose A.
  • 通讯作者:
    Bengoechea, Jose A.
Klebsiella pneumoniae hijacks the Toll-IL-1R protein SARM1 in a type I IFN-dependent manner to antagonize host immunity.
  • DOI:
    10.1016/j.celrep.2022.111167
  • 发表时间:
    2022-08-09
  • 期刊:
  • 影响因子:
    8.8
  • 作者:
    Feriotti, Claudia;Sa-Pessoa, Joana;Calderon-Gonzalez, Ricardo;Gu, Lili;Morris, Brenda;Sugisawa, Ryoichi;Insua, Jose L.;Carty, Michael;Dumigan, Amy;Ingram, Rebecca J.;Kissenpfening, Adrien;Bowie, Andrew G.;Bengoechea, Jose A.
  • 通讯作者:
    Bengoechea, Jose A.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jose Bengoechea其他文献

Jose Bengoechea的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jose Bengoechea', 18)}}的其他基金

Characterization of Klebseilla pneumoniae T6SS nanoweapon and its role in the dissemination of antimicrobial genes and virulence factors.
肺炎克雷伯氏菌 T6SS 纳米武器的表征及其在抗菌基因和毒力因子传播中的作用。
  • 批准号:
    BB/V007939/1
  • 财政年份:
    2021
  • 资助金额:
    $ 59.67万
  • 项目类别:
    Research Grant
Klebsiella pneumonaie anti-immunology: exploiting mTORC1 to control cell-intrinsic immunity.
肺炎克雷伯菌抗免疫学:利用 mTORC1 控制细胞内在免疫。
  • 批准号:
    MR/V032496/1
  • 财政年份:
    2021
  • 资助金额:
    $ 59.67万
  • 项目类别:
    Research Grant
COVID-19: role of co-infections, and drug repurposing for treament
COVID-19:合并感染的作用以及重新利用药物进行治疗
  • 批准号:
    BB/V006576/1
  • 财政年份:
    2020
  • 资助金额:
    $ 59.67万
  • 项目类别:
    Research Grant
Klebsiella anti-immunology: exploiting proteins with a eukaryotic SEFIR domain
克雷伯氏菌抗免疫学:利用具有真核 SEFIR 结构域的蛋白质
  • 批准号:
    BB/T001976/1
  • 财政年份:
    2019
  • 资助金额:
    $ 59.67万
  • 项目类别:
    Research Grant
Macrophage sabotage: undermining macrophage signalling by Klebsiella pneumoniae
巨噬细胞破坏:肺炎克雷伯菌破坏巨噬细胞信号传导
  • 批准号:
    BB/P006078/1
  • 财政年份:
    2017
  • 资助金额:
    $ 59.67万
  • 项目类别:
    Research Grant
MICA: Host-directed therapeutics to combat bacterial infections
MICA:对抗细菌感染的宿主导向疗法
  • 批准号:
    MR/R005893/1
  • 财政年份:
    2017
  • 资助金额:
    $ 59.67万
  • 项目类别:
    Research Grant
Klebsiella pneumoniae type VI secretion system: a weapon for innate immunity warfare
VI型肺炎克雷伯菌分泌系统:先天免疫战的武器
  • 批准号:
    BB/N00700X/1
  • 财政年份:
    2016
  • 资助金额:
    $ 59.67万
  • 项目类别:
    Research Grant
Deciphering Klebsiella pneumoniae strategies to subvert host defences
破译肺炎克雷伯菌颠覆宿主防御的策略
  • 批准号:
    BB/L007223/1
  • 财政年份:
    2014
  • 资助金额:
    $ 59.67万
  • 项目类别:
    Research Grant

相似海外基金

BBSRC-NSF/BIO: An AI-based domain classification platform for 200 million 3D-models of proteins to reveal protein evolution
BBSRC-NSF/BIO:基于人工智能的域分类平台,可用于 2 亿个蛋白质 3D 模型,以揭示蛋白质进化
  • 批准号:
    BB/Y000455/1
  • 财政年份:
    2024
  • 资助金额:
    $ 59.67万
  • 项目类别:
    Research Grant
BBSRC-NSF/BIO: An AI-based domain classification platform for 200 million 3D-models of proteins to reveal protein evolution
BBSRC-NSF/BIO:基于人工智能的域分类平台,可用于 2 亿个蛋白质 3D 模型,以揭示蛋白质进化
  • 批准号:
    BB/Y001117/1
  • 财政年份:
    2024
  • 资助金额:
    $ 59.67万
  • 项目类别:
    Research Grant
22-BBSRC/NSF-BIO Building synthetic regulatory units to understand the complexity of mammalian gene expression
22-BBSRC/NSF-BIO 构建合成调控单元以了解哺乳动物基因表达的复杂性
  • 批准号:
    BB/Y008898/1
  • 财政年份:
    2024
  • 资助金额:
    $ 59.67万
  • 项目类别:
    Research Grant
22-BBSRC/NSF-BIO - Interpretable & Noise-robust Machine Learning for Neurophysiology
22-BBSRC/NSF-BIO - 可解释
  • 批准号:
    BB/Y008758/1
  • 财政年份:
    2024
  • 资助金额:
    $ 59.67万
  • 项目类别:
    Research Grant
22-BBSRC/NSF-BIO: Community-dependent CRISPR-cas evolution and robust community function
22-BBSRC/NSF-BIO:群落依赖性 CRISPR-cas 进化和强大的群落功能
  • 批准号:
    BB/Y008774/1
  • 财政年份:
    2024
  • 资助金额:
    $ 59.67万
  • 项目类别:
    Research Grant
20-BBSRC/NSF-BIO Regulatory control of innate immune response in marine invertebrates
20-BBSRC/NSF-BIO 海洋无脊椎动物先天免疫反应的调节控制
  • 批准号:
    BB/W017865/1
  • 财政年份:
    2024
  • 资助金额:
    $ 59.67万
  • 项目类别:
    Research Grant
UKRI/BBSRC-NSF/BIO: Interpretable and Noise-Robust Machine Learning for Neurophysiology
UKRI/BBSRC-NSF/BIO:用于神经生理学的可解释且抗噪声的机器学习
  • 批准号:
    2321840
  • 财政年份:
    2023
  • 资助金额:
    $ 59.67万
  • 项目类别:
    Continuing Grant
BBSRC Institute Strategic Programme: Microbes and Food Safety
BBSRC 研究所战略计划:微生物与食品安全
  • 批准号:
    BB/X018814/1
  • 财政年份:
    2023
  • 资助金额:
    $ 59.67万
  • 项目类别:
    Research Grant
BBSRC IAA University of Southampton
BBSRC IAA 南安普顿大学
  • 批准号:
    BB/X51231X/1
  • 财政年份:
    2023
  • 资助金额:
    $ 59.67万
  • 项目类别:
    Research Grant
BBSRC IAA University of Reading
BBSRC IAA 雷丁大学
  • 批准号:
    BB/X512308/1
  • 财政年份:
    2023
  • 资助金额:
    $ 59.67万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了